



FIG. 1

Pursuant to 37 C.F.R. §1.10, I hereby certify that the attached document was submitted to the USPTO by U.S. Express Mail No. ER162019628US on March 2, 2804.


Aimee V. Hilado








<u>FIG.3</u>



















FIG.8























FIG.20A




FIG.20B





FIG.21






FIG.23A






FIG.23B



I. TARGET ZONE COATED WITH CD4 ANTIBODIES






FIG.25A




FIG.25B